David J Pasta

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8443994/publications.pdf

Version: 2024-02-01

109 papers	7,865 citations	43973 48 h-index	86 g-index
110	110	110	7210 citing authors
all docs	docs citations	times ranked	

#	Article	IF	CITATIONS
1	Epidemiologic Study of Cystic Fibrosis: 25 years of observational research. Pediatric Pulmonology, 2021, 56, 823-836.	1.0	11
2	Long-term safety and efficacy of tezacaftor–ivacaftor in individuals with cystic fibrosis aged 12 years or older who are homozygous or heterozygous for Phe508del CFTR (EXTEND): an open-label extension study. Lancet Respiratory Medicine,the, 2021, 9, 733-746.	5.2	33
3	The Nexus Narcolepsy Registry: methodology, study population characteristics, and patterns and predictors of narcolepsy diagnosis. Sleep Medicine, 2021, 84, 405-414.	0.8	11
4	Assessing the impact of sodium oxybate treatment on functioning, productivity, and health-related quality of life in patients with narcolepsy: findings from the Nexus Narcolepsy Registry (waves $1\hat{a}\in$ "4). Sleep Medicine, 2021, 84, 380-388.	0.8	5
5	Rapid lung function decline in adults with early-stage cystic fibrosis lung disease. Journal of Cystic Fibrosis, 2020, 19, 527-533.	0.3	1
6	Lung function changes before and after pulmonary exacerbation antimicrobial treatment in cystic fibrosis. Pediatric Pulmonology, 2020, 55, 828-834.	1.0	21
7	Pulmonary exacerbations and acute declines in lung function in patients with cystic fibrosis. Journal of Cystic Fibrosis, 2018, 17, 496-502.	0.3	15
8	Association of High-Dose Ibuprofen Use, Lung Function Decline, and Long-Term Survival in Children with Cystic Fibrosis. Annals of the American Thoracic Society, 2018, 15, 485-493.	1.5	52
9	Cystic fibrosis clinical characteristics associated with dornase alfa treatment regimen change. Pediatric Pulmonology, 2018, 53, 43-49.	1.0	6
10	Medical Expenditures and Earnings Losses Among <scp>US</scp> Adults With Arthritis in 2013. Arthritis Care and Research, 2018, 70, 869-876.	1.5	150
11	Treatment Setting and Outcomes of Cystic Fibrosis Pulmonary Exacerbations. Annals of the American Thoracic Society, 2018, 15, 225-233.	1.5	32
12	Lung function decline is delayed but not decreased in patients with cystic fibrosis and the R117H gene mutation. Journal of Cystic Fibrosis, 2018, 17, 503-510.	0.3	14
13	BMI fails to identify poor nutritional status in stunted children with CF. Journal of Cystic Fibrosis, 2017, 16, 158-160.	0.3	20
14	Risk factors for mortality before age 18 years in cystic fibrosis. Pediatric Pulmonology, 2017, 52, 909-915.	1.0	71
15	Patients with Cystic Fibrosis and a G551D or Homozygous F508del Mutation: Similar Lung Function Decline. American Journal of Respiratory and Critical Care Medicine, 2017, 195, 1673-1676.	2.5	14
16	Relationship of Antibiotic Treatment to Recovery after Acute FEV ₁ Decline in Children with Cystic Fibrosis. Annals of the American Thoracic Society, 2017, 14, 937-942.	1.5	35
17	Assessment of safety and efficacy of long-term treatment with combination lumacaftor and ivacaftor therapy in patients with cystic fibrosis homozygous for the F508del-CFTR mutation (PROGRESS): a phase 3, extension study. Lancet Respiratory Medicine, the, 2017, 5, 107-118.	5.2	235
18	Comparison of FEV1 reference equations for evaluating a cystic fibrosis therapeutic intervention. Pediatric Pulmonology, 2017, 52, 1013-1019.	1.0	6

#	Article	IF	CITATIONS
19	Forced Expiratory Volume in 1 Second Variability Helps Identify Patients with Cystic Fibrosis at Risk of Greater Loss of Lung Function. Journal of Pediatrics, 2016, 169, 116-121.e2.	0.9	44
20	Decline in lung function does not predict future decline in lung function in cystic fibrosis patients. Pediatric Pulmonology, 2015, 50, 856-862.	1.0	19
21	Antibiotic treatment of signs and symptoms of pulmonary exacerbations: A comparison by care site. Pediatric Pulmonology, 2015, 50, 431-440.	1.0	43
22	Pulmonary function outcomes for assessing cystic fibrosis care. Journal of Cystic Fibrosis, 2015, 14, 376-383.	0.3	16
23	Treatment and demographic factors affecting time to next pulmonary exacerbation in cystic fibrosis. Journal of Cystic Fibrosis, 2015, 14, 763-769.	0.3	38
24	Sustained Benefit from Ivacaftor Demonstrated by Combining Clinical Trial and Cystic Fibrosis Patient Registry Data. American Journal of Respiratory and Critical Care Medicine, 2015, 192, 836-842.	2.5	198
25	Improvements in Lung Function and Height among Cohorts of 6-Year-Olds with Cystic Fibrosis from 1994 to 2012. Journal of Pediatrics, 2014, 165, 1091-1097.e2.	0.9	24
26	Early childhood wheezing is associated with lower lung function in cystic fibrosis. Pediatric Pulmonology, 2014, 49, 745-750.	1.0	21
27	Liver Involvement in the Hispanic Population of North America With Cystic Fibrosis. Journal of Pediatric Gastroenterology and Nutrition, 2014, 59, 476-479.	0.9	7
28	Clinical use of tobramycin inhalation solution (TOBI®) shows sustained improvement in FEV ₁ in cystic fibrosis. Pediatric Pulmonology, 2014, 49, 529-536.	1.0	16
29	Treatment complexity in cystic fibrosis: Trends over time and associations with site-specific outcomes. Journal of Cystic Fibrosis, 2013, 12, 461-467.	0.3	125
30	Changing thresholds and incidence of antibiotic treatment of cystic fibrosis pulmonary exacerbations, 1995–2005. Journal of Cystic Fibrosis, 2013, 12, 332-337.	0.3	18
31	Evidence of diminished FEV1 and FVC in 6-year-olds followed in the European cystic fibrosis patient registry, 2007–2009. Journal of Cystic Fibrosis, 2013, 12, 786-789.	0.3	8
32	Probability of Treatment Following Acute Decline in Lung Function in Children with Cystic Fibrosis is Related to Baseline Pulmonary Function. Journal of Pediatrics, 2013, 163, 1152-1157.e2.	0.9	36
33	Oral, inhaled, and intravenous antibiotic choice for treating pulmonary exacerbations in cystic fibrosis. Pediatric Pulmonology, 2013, 48, 666-673.	1.0	99
34	Pulmonary exacerbations in cystic fibrosis: Young children with characteristic signs and symptoms. Pediatric Pulmonology, 2013, 48, 649-657.	1.0	44
35	Long-term Effects of Pregnancy and Motherhood on Disease Outcomes of Women with Cystic Fibrosis. Annals of the American Thoracic Society, 2013, 10, 213-219.	1.5	56
36	Psychometric evaluation of the Cystic Fibrosis Questionnaire-Revised in a national sample. Quality of Life Research, 2012, 21, 1267-1278.	1. 5	95

#	Article	IF	Citations
37	Risk factors for rate of decline in FEV1 in adults with cystic fibrosis. Journal of Cystic Fibrosis, 2012, 11, 405-411.	0.3	96
38	Lung function decline from adolescence to young adulthood in cystic fibrosis. Pediatric Pulmonology, 2012, 47, 135-143.	1.0	99
39	Risk factors for onset of persistent respiratory symptoms in children with cystic fibrosis. Pediatric Pulmonology, 2012, 47, 966-972.	1.0	15
40	Benign Prostatic Hyperplasia Evaluation and Management by Urologists and Primary Care Physicians: Practice Patterns From the Observational BPH Registry. Journal of Urology, 2011, 186, 971-976.	0.2	39
41	Socioeconomic Status and the Likelihood of Antibiotic Treatment for Signs and Symptoms of Pulmonary Exacerbation in Children with Cystic Fibrosis. Journal of Pediatrics, 2011, 159, 819-824.e1.	0.9	36
42	Longitudinal assessment of healthâ€related quality of life in an observational cohort of patients with cystic fibrosis. Pediatric Pulmonology, 2011, 46, 36-44.	1.0	85
43	Clinical use of dornase alfa is associated with a slower rate of FEV ₁ decline in cystic fibrosis. Pediatric Pulmonology, 2011, 46, 545-553.	1.0	76
44	Impact of Socioeconomic Status, Race, and Ethnicity on Quality of Life in Patients With Cystic Fibrosis in the United States. Chest, 2010, 137, 642-650.	0.4	110
45	Biodemographic modeling of the links between fertility motivation and fertility outcomes in the NLSY79. Demography, 2010, 47, 393-414.	1.2	33
46	Efficacy of osteopathic manipulation as an adjunctive treatment for hospitalized patients with pneumonia: a randomized controlled trial. Osteopathic Medicine and Primary Care, 2010, 4, 2.	0.5	72
47	Pulmonary outcome prediction (POP) tools for cystic fibrosis patients. Pediatric Pulmonology, 2010, 45, 1156-1166.	1.0	39
48	Trends in the use of routine therapies in cystic fibrosis: 1995-2005. Pediatric Pulmonology, 2010, 45, 1167-1172.	1.0	58
49	Year-to-year changes in lung function in individuals with cystic fibrosis. Journal of Cystic Fibrosis, 2010, 9, 250-256.	0.3	98
50	Endometriosis fertility index: the new, validated endometriosis staging system. Fertility and Sterility, 2010, 94, 1609-1615.	0.5	327
51	Fertility Motivations of Youth Predict Later Fertility Outcomes: A Prospective Analysis of National Longitudinal Survey of Youth Data. Biodemography and Social Biology, 2010, 56, 1-23.	0.4	32
52	Trends in Medical Care Expenditures of US Adults with Arthritis and Other Rheumatic Conditions 1997 to 2005. Journal of Rheumatology, 2009, 36, 2531-2538.	1.0	39
53	Patterns of Care in Community-Based Oncology Practices for Anemia Associated With Myelosuppressive Chemotherapy. Journal of Oncology Practice, 2009, 5, 236-243.	2.5	1
54	The Authors' Reply. Clinical Drug Investigation, 2009, 29, 144.	1.1	0

#	Article	IF	CITATIONS
55	Shifting patterns of inhaled antibiotic use in cystic fibrosis. Pediatric Pulmonology, 2008, 43, 874-881.	1.0	56
56	The impact of incident methicillin resistant <i>Staphylococcus aureus</i> detection on pulmonary function in cystic fibrosis. Pediatric Pulmonology, 2008, 43, 1117-1123.	1.0	77
57	Development of a fatigue and functional impact scale in anemic cancer patients receiving chemotherapy. Cancer, 2008, 113, 1480-1488.	2.0	16
58	Insurance and quality of life in men with prostate cancer: data from the Cancer of the Prostate Strategic Urological Research Endeavor. BJU International, 2008, 101, 691-697.	1.3	20
59	Relationship between Inhaled Corticosteroid Therapy and Rate of Lung Function Decline in Children with Cystic Fibrosis. Journal of Pediatrics, 2008, 153, 746-751.e2.	0.9	72
60	Long-Term Therapeutic Drug Monitoring of Risperidone and Olanzapine Identifies Altered Steady-State Pharmacokinetics. Clinical Drug Investigation, 2008, 28, 553-564.	1.1	8
61	Comparison of levalbuterol and racemic albuterol in hospitalized patients with acute asthma or COPD: A 2-week, multicenter, randomized, open-label study. Clinical Therapeutics, 2008, 30, 989-1002.	1.1	21
62	Watchful Waiting and Health Related Quality of Life for Patients With Localized Prostate Cancer: Data From CaPSURE. Journal of Urology, 2008, 179, S14-8.	0.2	10
63	The measurement of childbearing motivation in couples considering the use of assisted reproductive technology. Biodemography and Social Biology, 2008, 54, 8-32.	0.4	17
64	Quality of Life for Men Receiving a Second Treatment for Prostate Cancer. Journal of Urology, 2007, 177, 273-279.	0.2	8
65	Medical care expenditures and earnings losses among persons with arthritis and other rheumatic conditions in 2003, and comparisons with 1997. Arthritis and Rheumatism, 2007, 56, 1397-1407.	6.7	207
66	Risk Factors For Rate of Decline in Forced Expiratory Volume in One Second in Children and Adolescents with Cystic Fibrosis. Journal of Pediatrics, 2007, 151, 134-139.e1.	0.9	384
67	Impact of Pregnancy on Women With Cystic Fibrosis. Chest, 2006, 129, 706-711.	0.4	165
68	Correlation of thyroid stimulating hormone (TSH) level with pregnancy outcome in women undergoing in vitro fertilization. American Journal of Obstetrics and Gynecology, 2006, 194, 1668-1674.	0.7	49
69	Multiinstitutional validation of the UCSF cancer of the prostate risk assessment for prediction of recurrence after radical prostatectomy. Cancer, 2006, 107, 2384-2391.	2.0	129
70	Early Coronary Revascularization Diminishes the Risk of Ischemic Stroke With Acute Myocardial Infarction. Stroke, 2006, 37, 2546-2551.	1.0	21
71	Trends in Management and Outcomes of Patients With Acute Myocardial Infarction Complicated by Cardiogenic Shock. JAMA - Journal of the American Medical Association, 2005, 294, 448.	3.8	581
72	OBESITY AND PROSTATE CANCER CLINICAL RISK FACTORS AT PRESENTATION: DATA FROM CaPSURE. Journal of Urology, 2005, 173, 732-736.	0.2	53

#	Article	IF	Citations
73	THE IMPACT OF OBESITY ON HEALTH RELATED QUALITY OF LIFE BEFORE AND AFTER RADICAL PROSTATECTOMY (DATA FROM CaPSURE). Journal of Urology, 2005, 173, 1132-1138.	0.2	62
74	THE UNIVERSITY OF CALIFORNIA, SAN FRANCISCO CANCER OF THE PROSTATE RISK ASSESSMENT SCORE: A STRAIGHTFORWARD AND RELIABLE PREOPERATIVE PREDICTOR OF DISEASE RECURRENCE AFTER RADICAL PROSTATECTOMY. Journal of Urology, 2005, 173, 1938-1942.	0.2	592
75	Impact of obesity on prostate cancer recurrence after radical prostatectomy: Data from CaPSURE. Urology, 2005, 66, 1060-1065.	0.5	135
76	Longitudinal assessment of changes in sexual function and bother in patients treated with external beam radiotherapy or brachytherapy, with and without neoadjuvant androgen ablation: Data from CaPSURE. International Journal of Radiation Oncology Biology Physics, 2004, 60, 1066-1075.	0.4	24
77	Medical care expenditures and earnings losses of persons with arthritis and other rheumatic conditions in the United States in 1997: Total and incremental estimates. Arthritis and Rheumatism, 2004, 50, 2317-2326.	6.7	82
78	Patterns of Secondary Cancer Treatment for Biochemical Failure Following Radical Prostatectomy:: Data From CaPSURE. Journal of Urology, 2004, 171, 215-219.	0.2	45
79	Predicting Quality of Life After Radical Prostatectomy: Results From CaPSURE. Journal of Urology, 2004, 171, 703-708.	0.2	165
80	BOWEL FUNCTION AND BOTHER AFTER TREATMENT FOR EARLY STAGE PROSTATE CANCER: A LONGITUDINAL QUALITY OF LIFE ANALYSIS FROM CaPSURE. Journal of Urology, 2004, 172, 515-519.	0.2	71
81	WATCHFUL WAITING AND HEALTH RELATED QUALITY OF LIFE FOR PATIENTS WITH LOCALIZED PROSTATE CANCER: DATA FROM CaPSURE. Journal of Urology, 2004, 172, 1830-1834.	0.2	52
82	VALIDATION OF THE KATTAN PREOPERATIVE NOMOGRAM FOR PROSTATE CANCER RECURRENCE USING A COMMUNITY BASED COHORT: RESULTS FROM CANCER OF THE PROSTATE STRATEGIC UROLOGICAL RESEARCH ENDEAVOR (CAPSURE). Journal of Urology, 2004, 171, 2255-2259.	0.2	100
83	A framework for modelling fertility motivation in couples. Population Studies, 2004, 58, 193-205.	1.1	129
84	Obstructive lower urinary tract symptoms correlate with erectile dysfunction. Urology, 2004, 63, 1148-1152.	0.5	69
85	Fear of Cancer Recurrence in Patients Undergoing Definitive Treatment for Prostate Cancer: Results From CaPSURE. Journal of Urology, 2003, 170, 1931-1933.	0.2	92
86	Health Related Quality of Life Patterns in Patients Treated With Interstitial Prostate Brachytherapy for Localized Prostate Cancer—Data From CaPSURE. Journal of Urology, 2003, 170, 1822-1827.	0.2	60
87	Impact of patient educational level on treatment for patients with prostate cancer: data from CaPSURE. Urology, 2003, 62, 1035-1039.	0.5	40
88	The effect of the nurturant bonding system on child security of attachment and dependency. Biodemography and Social Biology, 2002, 49, 125-159.	0.4	5
89	Telephone assessment of functioning and well-being following stroke: Is it feasible?. Journal of Stroke and Cerebrovascular Diseases, 2002, 11, 80-87.	0.7	8
90	The Motivational Substrate of Unintended and Unwanted Pregnancy 1. Journal of Applied Biobehavioral Research, 2002, 7, 1-29.	2.0	19

#	Article	IF	CITATIONS
91	The association between socioeconomic status, health insurance coverage, and quality of life in men with prostate cancer. Journal of Clinical Epidemiology, 2001, 54, 350-358.	2.4	142
92	Motivational antecedents to contraceptive method change following a pregnancy scare: A couple analysis. Biodemography and Social Biology, 2001, 48, 256-277.	0.4	3
93	URINARY FUNCTION AND BOTHER AFTER RADICAL PROSTATECTOMY OR RADIATION FOR PROSTATE CANCER:: A LONGITUDINAL, MULTIVARIATE QUALITY OF LIFE ANALYSIS FROM THE CANCER OF THE PROSTATE STRATEGIC UROLOGIC RESEARCH ENDEAVOR. Journal of Urology, 2000, 164, 1973-1977.	0.2	141
94	Early Family Environment, Reproductive Strategy, and Contraceptive Behavior: Testing a Genetic Hypothesis., 2000, , 183-230.		16
95	Genetic Influences on Childbearing Motivation: Further Testing a Theoretical Framework. , 2000, , 35-66.		15
96	Approaches to Missing Data Inference Results from CaPSURE. Pharmacoeconomics, 1999, 15, 197-204.	1.7	6
97	Sexual function and bother after radical prostatectomy or radiation for prostate cancer: multivariate quality-of-life analysis from CaPSURE. Urology, 1999, 54, 503-508.	0.5	274
98	Risperidone Dose and Blood Level Variability. Journal of Clinical Psychopharmacology, 1997, 17, 478-484.	0.7	38
99	Use of the Health Utilities Index With Stroke Patients and Their Caregivers. Stroke, 1997, 28, 1888-1894.	1.0	79
100	Couple disagreement: Effects on the formation and implementation of fertility decisions. Personal Relationships, 1996, 3, 307-336.	0.9	42
101	The Relative Influence of Husbands and Wives on the Choice and Use of Oral Contraception, a Diaphragm, and Condoms1. Journal of Applied Social Psychology, 1996, 26, 1749-1774.	1.3	21
102	Behavioral Intentions: Which Ones Predict Fertility Behavior in Married Couples?1. Journal of Applied Social Psychology, 1995, 25, 530-555.	1.3	155
103	How does childbearing affect fertility motivations and desires?. Social Biology, 1995, 42, 185-198.	0.4	26
104	Haloperidol Dose and Blood Level Variability. Journal of Clinical Psychopharmacology, 1995, 15, 334-340.	0.7	20
105	The Psychology of Child Timing: A Measurement Instrument and a Model1. Journal of Applied Social Psychology, 1994, 24, 218-250.	1.3	61
106	Motivational and nonmotivational determinants of child-number desires. Population and Environment, 1993, 15, 113-138.	1.3	38
107	Laparoscopic endometriosis treatment: is it better?. Fertility and Sterility, 1993, 59, 35-44.	0.5	102
108	Comparison of CO2 laser laparoscopy with laparotomy for treatment of endometriomata. Fertility and Sterility, 1992, 57, 965-973.	0.5	78

 #	Article	IF	CITATIONS
109	A model of fertility motivation, desires, and expectations early in women's reproductive careers. Biodemography and Social Biology, 1988, 35, 236-250.	0.4	8